Emerging Company Showcase

1. ARETEON PTE LTD
亚绿基公司
We create possibilities in veterinary therapeutics
INVESTMENT/BUSINESS
OPPORTUNITY
PATENTED, NON-
BACTERIAL RESISTANCE
ANTIMICROBIAL AND
ANTI-FUNGAL DRUG

2. ©AreteonPteLtd
2ANTIMICROBIAL DRUG RESISTANCE
1. The first anti-microbial
drug was discovered in
1929 : Penicillin
2. The last true antibiotic
was discovered in 1960s
3. Today, there are only 7
antibiotic scaffolds. All
the so-called recent
“discoveries” are based
on manipulating the
existing scaffolds. This
encourages multi-drug
resistance very rapidly

3. ©AreteonPteLtd
3ANTIMICROBIAL DRUG RESISTANCE
Antimicrobial drugs need to
enter the bacterium to be able
to kill the bacterium or stop it
from replicating
Mode of action #1

4. ©AreteonPteLtd
4ANTIMICROBIAL DRUG RESISTANCE
Mode of action #2
Antimicrobial drugs need to
breakthrough the biofilm that
protects the bacteria

5. ©AreteonPteLtd
5DMDC: NOVEL MODE OF ACTION
Patent pending; PCT/SG2014/000053
Poly-cationic chitosan-based polymer
Quaternary ammonium (positively charged)
Glucosamine moiety
PEG

6. ©AreteonPteLtd
6DMDC: NOVEL MODE OF ACTION
Patent pending; PCT/SG2014/000053
RNA
DNA
Cell wall
(negatively charged)
Staphylococcus aureus
DMDC
(positively charged)
Electrostatic
bonding

7. ©AreteonPteLtd
7DMDC: NOVEL MODE OF ACTION
Patent pending; PCT/SG2014/000053
Staphylococcus aureus
DMDC
(positively charged)
Bacterial lysis =
bactericidal

8. ©AreteonPteLtd
8DMDC: NOVEL MODE OF ACTION
Patent pending; PCT/SG2014/000053
Does not need to penetrate the
bacterium
Cannot be neutralized by the
enzymes in the bacterium
No risk of bacterial resistance
to DMDC

9. ©AreteonPteLtd
9DMDC: NOVEL MODE OF ACTION
Patent pending; PCT/SG2014/000053
Treatment
by DMDC
Electron-microscopy of destruction of S. aureus
Perforation of cell wall =
Death of bacteria

10. ©AreteonPteLtd
10DMDC: TRIALS CONDUCTED
Patent pending; PCT/SG2014/000053
Efficacy: 4% shampoo formulation
Observation
parameters
Treatment period
Day 0 Day 7 Day 14 Day 21
Pruritus1
Owner
Clinician
4.33
4.00
3.33
3.33
3.00
2.67
2.33
2.33
Bacterial Load2
Papules
Pustules
Skin flakes
2.28
2.56
2.00
1.67
2.11
1.50
1.44
1.72
1.00
0.56
0.94
0.00
Symptoms 3
Papules
Pustules
Skin flakes
Scabs/Dandruff
3.67
3.00
2.50
3.50
3.67
2.67
2.50
2.50
3.00
2.33
1.50
2.50
2.33
2.33
1.50
2.00
Fur Coat4
Shine
Odour
Fur loss
4.00
3.67
4.00
3.67
2.67
4.00
3.00
2.33
4.00
2.33
1.67
3.00

11. ©AreteonPteLtd
11DMDC: 3X Minimum Inhibitory
Concentration Trials Conducted for
“OralGarde” Veterinary Mouth-Spray
Patent pending; PCT/SG2014/000053
S. aureus (μg/mL) E. coli (μg/mL) P. aeruginosa (μg/mL) MRSA (μg/mL)
12.5 25 25 15
12.5 25 25 15
12.5 25 25 15

12. ©AreteonPteLtd
12DMDC: TRIALS CONDUCTED
Patent pending; PCT/SG2014/000053
Safety: Acute oral toxicity (OECD guideline 423)
1. LD50 > 2,000 mg/kg of
body weight.
2. All rats appeared normal
thereafter till euthanized. No
untoward clinical signs were
observed during this period.
3. All rats did not have significant
lesions observed on gross
pathology.

13. ©AreteonPteLtd
13DMDC: MILESTONES ACHIEVED
Patent pending; PCT/SG2014/000053
S$600,000
seed funding
by business
angel in May
2012
Successful
completion of
preliminary
trials on
potency, efficacy
and safety on
Sep 2013
Optimization of
chemical
synthesis at mass
- production scale
with significantly
improved
potency.
Sales launch in Q1 2017
new Topical Products
formulated with DMDC
significantly improved
potency and raise capital
for expansion.
S$725,000 Singapore
government funding
between Jan 2013 and
Dec 2015

14. ©AreteonPteLtd
14
ARETEON PTE LTD
亚绿基公司
We create possibilities in veterinary therapeutics
ARETEON PTE LTD
19 Tai Seng Avenue, #06-19
Home-Fix Building,
Singapore 534054
THANK YOU !